Merck - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups by Category

All Categories ... by Company » ... Merck

A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)

Condition: Infant, Small for Gestational Age
Intervention: Drug: recombinant somatropin
Sponsor: Merck KGaA
Recruiting - verified March 2010
Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients

Condition: Colorectal Neoplasms
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

Condition: Ovulation Induction
Intervention: Drug: Recombinant FSH (follitropin alpha)
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes

Condition: Multiple Sclerosis
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients

Condition: Hypertension
Intervention: Drug: Lodoz (Combination of bisoprolol and hydrochlorothiazide)
Sponsor: Merck KGaA
Recruiting - verified March 2010
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Reoccurrence

Condition: Psoriasis
Interventions: Drug: Cyclosporins; Drug: Retinoids; Drug: Systemic corticosteroids; Drug: Methotrexate; Drug: Systemic corticosteroids/methotrexate
Sponsor: Merck KGaA
Completed - verified March 2010
A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Conditions: Infertility; Ovulation Induction
Interventions: Drug: Lutropin alfa for injection (r-hLH) + r-hFSH; Drug: r-hFSH preparation
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents

Conditions: Varicella; Herpes Zoster
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period

Condition: Phenylketonuria
Intervention: Drug: Kuvan® (Sapropterin dihydrochloride)
Sponsors: Merck KGaA; Smerud Medical Research International AS
Not yet recruiting - verified March 2010
Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)

Condition: Arthritis, Rheumatoid
Intervention: Drug: Prednisone
Sponsor: Merck KGaA
Recruiting - verified February 2010
An Open, Non-comparative, Registration Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

Condition: Hypogonadism
Intervention: Drug: r-hLH
Sponsor: Merck KGaA
Completed - verified March 2010
A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)

Condition: Infertility
Interventions: Drug: r-hCG; Drug: Urinary-hCG
Sponsor: Merck KGaA
Completed - verified March 2010
A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)

Condition: Infertility
Interventions: Drug: Micronised Progesterone; Drug: Progesterone
Sponsor: Merck KGaA
Completed - verified March 2010
Metabolic Endocrinology and Growth Hormone in Adults: An Observational Study on the Prescription of the Growth Hormone Saizen for Adults in France and Follow-up of Treated Patients

Condition: Adult Growth Hormone Deficiency
Intervention:
Sponsor: Merck KGaA
Active, not recruiting - verified March 2010
An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

Condition: Multifollicular Stimulation
Intervention: Drug: Recombinant-follicle stimulating hormone (r-FSH)
Sponsor: Merck KGaA
Active, not recruiting - verified March 2010
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Condition: Colorectal Neoplasms
Intervention: Drug: Erbitux (Cetuximab)
Sponsor: Merck KGaA
Recruiting - verified March 2010
Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network

Condition: HIV-1 Infections
Intervention:
Sponsors: Merck; Kaiser Permanente
Active, not recruiting - verified February 2010
GARDASIL™ Vaccine Impact in Population Study

Condition: Human Papillomavirus Infections
Intervention:
Sponsors: Merck; Danish Cancer Society; Icelandic Cancer Society; The Cancer Registry of Norway; Karolinska Institutet
Active, not recruiting - verified February 2010
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis

Condition: Ankylosing Spondylitis
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
Observational Data Analysis in EuroSIDA

Condition: HIV-1 Infections
Intervention:
Sponsors: Merck; EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)
Active, not recruiting - verified February 2010
An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial

Condition: Cancer
Intervention:
Sponsors: Merck; Institute of Applied Economics Aps, Denmark
Not yet recruiting - verified February 2010
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™

Condition: Human Papillomavirus Infection
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
A Study to Evaluate the Relationship Between Treatment for Osteoporosis and Risk of Esophageal Cancer

Condition: Esophageal Cancer
Intervention:
Sponsors: Merck; World Health Information Science Consultants, LLC
Active, not recruiting - verified February 2010
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)

Condition: Multiple Sclerosis, Relapsing Remitting
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Condition: Multiple Sclerosis, Relapsing Remitting
Intervention: Drug: Rebif® New Formulation
Sponsor: Merck KGaA
Recruiting - verified March 2010
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients

Condition: Multiple Sclerosis, Relapsing Remitting
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
An Active-controlled, Clinical Trial to Assess Central Haemodynamic Effects of Bisoprolol in Hypertensive Patients

Condition: Hypertension
Interventions: Drug: Bisoprolol; Drug: Atenolol
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Conditions: Infertility; Ovulation Induction
Intervention: Drug: Lutropin alfa
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Interferon beta-1a; Drug: Placebo
Sponsor: Merck KGaA
Completed - verified March 2010
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: sitagliptin phosphate (+) metformin hydrochloride; Drug: Comparator: metformin; Drug: Comparator: sitagliptin; Drug: Comparator: Placebo
Sponsor: Merck
Not yet recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: sitagliptin phosphate; Drug: Comparator: placebo to pioglitazone; Drug: Comparator: placebo to sitagliptin; Drug: Comparator: pioglitazone; Drug: Comparator: glimepiride or gliclazide; Drug: Comparator: metformin; Drug: Comparator: pioglitazone rescue therapy
Sponsor: Merck
Not yet recruiting - verified February 2010
A Study of MK1775 in Combination With Topotecan/Cisplatin in Patients With Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: MK1775 + topotecan + cisplatin; Drug: Comparator: MK1775 + topotecan + cisplatin; Drug: Comparator: Placebo to MK1775 + topotecan + cisplatin
Sponsor: Merck
Not yet recruiting - verified February 2010
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Condition: Haematological Malignancies
Interventions: Drug: AS703569; Drug: AS703569
Sponsor: EMD Serono
Active, not recruiting - verified March 2010
ROTATEQ Reexamination Study

Condition: Gastroenteritis Rotavirus
Intervention:
Sponsor: Merck
Recruiting - verified February 2010
Re-examination Study of EMEND

Condition: Nausea and Vomiting Post Chemotherapy
Intervention:
Sponsor: Merck
Recruiting - verified February 2010
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

Condition: Healthy
Intervention: Drug: Famotidine
Sponsor: Ranbaxy Laboratories Limited
Completed - verified March 2010
Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention: Drug: Interferon-β-1a
Sponsor: Merck KGaA
Recruiting - verified February 2010
Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

Condition: Reproductive Techniques, Assisted
Interventions: Drug: r-hFSH and r-hLH; Drug: r-hFSH
Sponsor: Merck KGaA
Terminated - verified July 2004
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors

Condition: Solid Tumors
Interventions: Drug: MK2206 every other day; Drug: MK2206 once weekly
Sponsor: Merck
Recruiting - verified March 2010
A Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck in Korea

Condition: Head and Neck Cancer
Intervention: Drug: Cetuximab
Sponsor: Merck KGaA
Recruiting - verified February 2010
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers

Condition: Multiple Sclerosis
Intervention:
Sponsor: Merck KGaA
Recruiting - verified February 2010
Post-authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
Sponsor: Merck KGaA
Recruiting - verified March 2010
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina

Condition: Multiple Sclerosis
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Condition: Neoplasms, Squamous Cell
Intervention: Drug: Cetuximab
Sponsor: Merck KGaA
Recruiting - verified February 2010
An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)

Condition: Multifollicular Stimulation
Intervention: Drug: Gonal-F (Follitropin alfa)
Sponsor: Merck KGaA
Recruiting - verified February 2010
A Study of V503 Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds

Condition: Human Papillomavirus (HPV) Infections
Interventions: Biological: V503; Biological: Comparator: REPEVAX™ (Concomitant); Biological: Comparator: REPEVAX™ (Non-Concomitant)
Sponsor: Merck
Not yet recruiting - verified March 2010
A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

Condition: Infertility
Intervention:
Sponsor: Merck KGaA
Recruiting - verified February 2009
Bioequivalence Study of 2.5 mg Saxagliptin and 850 mg Glucophage Combination Formulations in Healthy Subjects

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin; Drug: Metformin
Sponsors: Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2010
To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen

Conditions: Infertility; Ovulation Induction
Interventions: Drug: Follitropin alfa liquid formulation; Drug: Follitropin beta liquid formulation
Sponsor: Merck KGaA
Completed - verified March 2010
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
Sponsor: Merck KGaA
Recruiting - verified February 2010
An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)

Condition: Hypertension
Intervention: Drug: Enalapril maleate (10 mg) + nitrendipine (20 mg)
Sponsor: Merck KGaA
Completed - verified February 2010
A Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea

Condition: Heart Failure, Congestive
Intervention: Drug: Bisoprolol
Sponsor: Merck KGaA
Recruiting - verified February 2010
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects

Condition: Dyslipidemia
Interventions: Drug: Niaspan; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified February 2010
Vytorin Reexamination Study

Condition: Atherosclerosis
Intervention:
Sponsor: Merck
Recruiting - verified February 2010
Lipid Management in Clinical Practice

Condition: Lipid Metabolism Disorder
Intervention:
Sponsor: Merck
Recruiting - verified February 2010
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam

Condition: Advanced Cancer
Interventions: Drug: ridaforolimus; Drug: midazolam
Sponsors: Merck; Ariad Pharmaceuticals
Not yet recruiting - verified February 2010
Ezetrol Re-examination Study

Condition: Hypercholesterolemia
Intervention:
Sponsor: Merck
Recruiting - verified February 2010
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Conditions: Blood Stream Infections; Candida
Intervention:
Sponsors: University of Houston; Merck
Active, not recruiting - verified January 2010
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

Condition: Healthy
Intervention: Drug: Famotidine
Sponsor: Ranbaxy Laboratories Limited
Completed - verified March 2010
A Post-marketing Surveillance Study of Erbitux (Cetuximab) in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Cetuximab
Sponsor: Merck KGaA
Not yet recruiting - verified March 2010
Safety and Tolerability of Odanacatib (MK0822)

Condition: Osteoporosis
Interventions: Drug: Odanacatib; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Condition: Infant, Small for Gestational Age
Intervention: Drug: Recombinant human growth hormone (r-hGH)
Sponsor: Merck KGaA
Terminated - verified April 2003
AS902330 in Cartilage Injury Repair (CIR)

Condition: Isolated Cartilage Injury of the Knee
Interventions: Drug: AS902330; Drug: AS902330; Drug: AS902330; Other: Placebo
Sponsor: EMD Serono
Not yet recruiting - verified February 2010

Merck - Database of Clinical Trials by Pharmaceutical Companies - Clinical Trials

Merck - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials